This is a technical overview of an INVAMED device within the oncology ablation portfolio. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. As a medical device manufacturer, INVAMED develops technologies in this area; the information here is educational and not medical advice.
Background: Percutaneous Tumor Ablation
Intracavitary hypothermia describes controlled temperature therapy delivered directly into a body cavity such as the bladder, and is generally positioned as an adjunct intended to enhance the penetration of intravesical chemotherapy. Thermal methods dominate the field: radiofrequency ablation (RFA) and microwave ablation (MWA) heat tissue to cytotoxic temperatures, while cryoablation instead freezes the target to lethal cold. Because ablation is a local therapy, tumor size, number, location relative to vessels and organs, and overall clinical status all influence whether it is appropriate, as determined by a multidisciplinary clinician team.
ThermoEdge RFA Platform: Overview
A versatile radiofrequency ablation platform designed for precise and effective management of diverse conditions, including minimally invasive, bloodless resections of liver and kidney tissues, cyst treatments, and endometrial ablation for reducing menstrual bleeding as a minimally invasive alternative to hysterectomy (per invamed.com content surfaced via search index).
Technical Specifications
Specifications per INVAMED product documentation; confirm current details in the official IFU.
| Attribute | Detail |
|---|---|
| Specification | Multi-application RF ablation platform (liver/kidney tissue resection, cysts, endometrial ablation) |
How It Works and Where It Fits
INVAMED groups its ablation portfolio by the energy modality and anatomical target, offering radiofrequency platforms for soft tissue and bone as well as an intracavitary hypothermia set. Each device is intended for use by trained clinicians under appropriate image guidance and per the instructions for use (IFU). Intraosseous ablation delivers energy directly into bone to target vertebral or spinal tumors, an environment that differs from soft tissue because of the dense, mineralized matrix involved. Intracavitary hypothermia delivers controlled temperature therapy directly into the bladder, and is generally described as an adjunct intended to enhance the penetration and effect of intravesical chemotherapy rather than as a standalone ablation.
Key Considerations
- Tumor size, number, and proximity to vessels and adjacent organs are central factors in deciding whether ablation is appropriate and which modality to use.
- Image guidance with ultrasound, CT, or other modalities supports accurate applicator placement and monitoring of the treatment zone.
- Manufacturer descriptions of INVAMED platforms reflect intended design and applications rather than guaranteed individual outcomes.
Frequently Asked Questions
What determines the ablation zone size?
Published sources note that factors such as generator power, applicator design, application time, and local blood flow influence the ablation zone, and settings are selected by the treating physician.
Who decides whether ablation is appropriate?
A qualified clinical team decides based on tumor characteristics and patient factors; this article is educational and not a treatment recommendation.
How is microwave ablation different from radiofrequency ablation?
Both are heat-based, but microwave ablation is often described as heating tissue faster and being less affected by the heat-sink effect near vessels, while RFA has a particularly deep evidence base; the choice is made by the clinician.
About INVAMED
Device availability and regulatory status vary by country. Please contact INVAMED or your authorized local distributor for current regulatory information applicable to your region.
Clinical and Technical Context
Image guidance, applicator trajectory, and the decision to treat percutaneously versus by another route remain clinical judgments made by the operator. Unlike heat-based methods, the mechanism relies on cold injury, and the choice among cryoablation, RFA, and MWA depends on tumor and patient factors weighed by the clinician. INVAMED's Fusion Intraosseous Radiofrequency Ablation System for Spinal Tumors is positioned specifically for intraosseous RF delivery in vertebral and spinal tumor ablation. RFA has an extensive track record in hepatocellular carcinoma (HCC), MWA is frequently applied to liver and lung tumors, and cryoablation is often described for renal cell carcinoma, though indications are always defined by the treating team.
Related on INVAMED
- Oncology Ablation — product category
- HyperTiss Intracavitary Hypothermia Set for Bladder Cancer Treatment — Technical Overview
- Understanding Percutaneous Thermal Ablation Electrodes
- What size tumor can be ablated (the 3 cm rule)?
Important Disclaimer
This content is educational and technical in nature and must not be interpreted as medical advice or as a promise of any clinical outcome. Individual results depend on many factors and can only be evaluated by a treating physician. Figures attributed to INVAMED reflect manufacturer or published data and are not a guarantee of results. All INVAMED devices are to be used by trained clinicians per the approved IFU, and availability is subject to local regulatory status.
Reviewed by the INVAMED Medical Affairs team. Content is educational and technical in nature.